[CLSTR]
< Back to situations

Monitor this situation.

[SITUATION] · [ACTIVE] · [HEALTH]

3 clusters · 12 sources · 6 days · First seen · Last updated

Upadacitinib clinical trials for alopecia areata

Overview

Two phase 3 clinical trials, UP-AA1 and UP-AA2, have demonstrated that the JAK inhibitor upadacitinib (brand name Rinvoq) shows significant promise in treating severe alopecia areata. The studies, published in JAMA Dermatology, involved approximately 1,400 adolescents and adults aged 12 to 64 with a Severity of Alopecia Tool (SALT) score of 50 or higher.

At the 24-week mark, approximately 45% of patients on a 15 mg dose and between 54% and 55% of those on a 30 mg dose achieved 80% or greater scalp hair coverage, compared to only 1% to 3% in the placebo group. Long-term data at 52 weeks indicated continued improvement, with 55% to 64% of patients maintaining at least 80% scalp coverage and between 27% and 37% achieving complete hair regrowth.

Upadacitinib functions by suppressing inflammatory pathways and interferon-gamma signaling that cause the immune system to attack hair follicles. Unlike traditional corticosteroid treatments that may require scalp injections, upadacitinib is administered orally.

AbbVie has submitted a supplemental new drug application to the US Food and Drug Administration (FDA) to seek approval for this use. While these results indicate substantial efficacy, upadacitinib is not yet approved for this specific condition; currently, ritlecitinib remains the only approved therapy for adolescent patients with alopecia areata.

Entities

upadacitinib · FDA · JAMA Dermatology · Rinvoq · JAMA Dermatology

Timeline

  1. 6 days ago

    [HEALTH] 6 sources
    Upadacitinib shows significant hair regrowth in severe alopecia areata trials

    Upadacitinib has shown significant potential for hair regrowth in severe alopecia areata patients during Phase 3 trials, leading AbbVie to seek FDA approval for the JAK inhibitor.

  2. 9 days ago

    [HEALTH] 2 sources
    Upadacitinib shows significant hair regrowth in severe alopecia areata trials

    Phase 3 trials show upadacitinib achieved at least 80 percent scalp hair coverage in roughly half of patients with severe alopecia areata at 24 weeks. FDA approval is currently pending.

  3. 12 days ago

    [HEALTH] 5 sources
    Upadacitinib shows promise in treating severe alopecia areata

    Clinical trials show the arthritis drug upadacitinib helps significant portions of patients with severe alopecia areata regrow hair, with some achieving full regrowth within a year.

Sources

consultantlive.com · dan.co.me · eadv.org · gbnews.com · haber.ba · hencse.hu · index.hr · jobbing.fr · news.abbvie.com · pelop.gr · world-today-news.com · ygeiamou.gr

This summary has been updated 1 time: see revision history